Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Retinal Biologics Market, by Indication
1.4.2 North America Retinal Biologics Market, by Drug Class
1.4.3 North America Retinal Biologics Market, by Distribution Channel
1.4.4 North America Retinal Biologics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies deployed in Retinal Biologics Market
Chapter 5. North America Retinal Biologics Market by Indication
5.1 North America Macular Degeneration Market by Country
5.2 North America Diabetic Retinopathy Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Retinal Biologics Market by Drug Class
6.1 North America VEGF-A Antagonist Market by Country
6.2 North America Others Market by Country
Chapter 7. North America Retinal Biologics Market by Distribution Channel
7.1 North America Hospital Pharmacy Market by Country
7.2 North America Retail Pharmacy Market by Country
7.3 North America Online Pharmacy Market by Country
Chapter 8. North America Retinal Biologics Market by Country
8.1 US Retinal Biologics Market
8.1.1 US Retinal Biologics Market by Indication
8.1.2 US Retinal Biologics Market by Drug Class
8.1.3 US Retinal Biologics Market by Distribution Channel
8.2 Canada Retinal Biologics Market
8.2.1 Canada Retinal Biologics Market by Indication
8.2.2 Canada Retinal Biologics Market by Drug Class
8.2.3 Canada Retinal Biologics Market by Distribution Channel
8.3 Mexico Retinal Biologics Market
8.3.1 Mexico Retinal Biologics Market by Indication
8.3.2 Mexico Retinal Biologics Market by Drug Class
8.3.3 Mexico Retinal Biologics Market by Distribution Channel
8.4 Rest of North America Retinal Biologics Market
8.4.1 Rest of North America Retinal Biologics Market by Indication
8.4.2 Rest of North America Retinal Biologics Market by Drug Class
8.4.3 Rest of North America Retinal Biologics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Novartis AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Amgen, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Approvals & Trials:
9.3.6 SWOT Analysis
9.4 Bayer AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Research & Development Expense
9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Approvals & Trials:
9.7.5.3 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Approvals & Trials:
9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 SWOT Analysis
9.1 Oxurion NV
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Research & Development Expenses
9.10.4 SWOT Analysis
Unique Offerings 